title: [Possible Pitfalls of Ipilimumab Therapy in Malignant Melanoma -  a Case Report].
abstract: BACKGROUND
  Metastatic melanoma is a malignancy with one of the highest mortality rates. However, with the introduction of new drugs during the last decade, the prognosis of patients began to improve. Ipilimumab is one of the first so  called modern drugs in melanoma treatment. The therapy is often complicated by adverse effects which are referred as immunerelated adverse events due to its mechanism of action.
  
  
  METHODS
  We present a case of 68-year- old women with metastatic melanoma who underwent treatment with ipilimumab. The patient encountered several adverse events during the treatment. Some of them are quite common (e.g. skin affections), others (e.g. endocrinopathies) are less frequent.
  
  
  CONCLUSIONS
  This case study highlights the need for close observation not only during the actual treatment with ipilimumab, but also several weeks or months after the last dose. This case study also demonstrates further need of education of doctors who do not usually come in to contact with such patients.
authors.forename: J
authors.initials: J
authors.lastname: Kopecký
authors.forename: O
authors.initials: O
authors.lastname: Kubeček
authors.forename: F
authors.initials: F
authors.lastname: Gabalec
authors.forename: P
authors.initials: P
authors.lastname: Hoffmann
authors.forename: I
authors.initials: I
authors.lastname: Svilias
mesh_terms: D000368:Aged; D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D000970:Antineoplastic Agents / Q000009:adverse effects*; D005260:Female; D006801:Humans; D000074324:Ipilimumab; D008545:Melanoma / Q000188:drug therapy*; D012878:Skin Neoplasms / Q000188:drug therapy*
chemical_list: D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents; D000074324:Ipilimumab